Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report

Fig. 1

Effects of pemafibrate on serum triglyceride in patients with severe hypertriglyceridemia. a Patient 1, b Patient 2, c Patient 3. Day 0 is the baseline when pemafibrate was administered. In Patient 2, after the first administration, the patient was not compliant to take the drug. Nearly 200 days after the treatment, he suspended taking pemafibrate. Approximately after 300 days, he restarted to take pemafibrate regularly. Triglyceride (mg/dL), HDL-C (mg/dL)

Back to article page